About Oppilan pharma ltd.

About company

Oppilan Pharma is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Oppilan Pharma's lead drug candidate, OPL-002, is a potent and selective modulator of sphingosine 1 phosphate receptor subtype 1 (S1P1) under development for the treatment of inflammatory bowel disease. The company initiated a Phase 1 clinical study with OPL-002 in December 2018.